Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: An overview of 3 randomized controlled trials

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Reich, Kristian [2 ]
Drew, Janice [3 ]
Peterson, Luke [4 ]
Lebwohl, Mark [5 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dermatologikum Hamburg & SCIderm Res Inst, Hamburg, Germany
[3] Dermira Inc, Menlo Pk, CA USA
[4] UCB Pharma, Raleigh, NC USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
3120
引用
收藏
页码：AB239 / AB239
页数：1
相关论文
共 50 条
  • [1] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of three randomized controlled trials
    Blauvelt, A.
    Reich, K.
    Lebwohl, M.
    Burge, D.
    Arendt, C.
    Peterson, L.
    Drew, J.
    Rolleri, R.
    Gottlieb, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E249 - E250
  • [2] Certolizumab Pegol in the Treatment of Patients with moderate to severe chronic Plaque-Psoriasis: An Overview of 3 randomized, controlled clinical Studies
    Lendl, Udo
    Blauvelt, Andrew
    Reich, Kristian
    Lebwohl, Mark
    Burge, Daniel
    Arendt, Catherine
    Peterson, Luke
    Drew, Janice
    Rolleri, Robert
    Gottlieb, Alice
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 15 - 16
  • [3] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
    Blauvelt, A.
    Reich, K.
    Lebwohl, M.
    Burge, D.
    Arendt, C.
    Peterson, L.
    Drew, J.
    Rolleri, R.
    Gottlieb, A. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) : 546 - 552
  • [4] Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis
    Lee, Arnold
    Scott, Lesley J.
    BIODRUGS, 2020, 34 (02) : 235 - 244
  • [5] Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis
    Arnold Lee
    Lesley J. Scott
    BioDrugs, 2020, 34 : 235 - 244
  • [6] A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis
    Coto-Segura, Pablo
    Segu-Verges, Cristina
    Martorell, Antonio
    Moreno-Ramirez, David
    Jorba, Guillem
    Junet, Valentin
    Guerri, Filippo
    Daura, Xavier
    Oliva, Baldomero
    Cara, Carlos
    Suarez-Magdalena, Olaya
    Abraham, Sonya
    Mas, Jose Manuel
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [7] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Tzanetakos, C.
    VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [8] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Kiri, S.
    Tzanetakos, C.
    VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [9] Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials
    Gottlieb, A. B.
    Thaci, D.
    Leonardi, C.
    Poulin, Y.
    Kavanagh, S.
    Boehnlein, M.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 54 - 54
  • [10] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1395 - 1406
12345